Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients

Status Recruiting

Clinical Trial Summary

This pilot trial studies how well serial liquid biopsies work in detecting microsatellite instability in participants with stage IV colorectal cancer. Serial liquid biopsies may help doctors learn better methods to track cancer in the bloodstream and how to use these to improve cancer treatments.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To test the hypothesis that there is high level of concordance between the electrophoretic mobility profile of microsatellite biomarkers in circulating cell-free deoxyribonucleic acid (ccfDNA) versus in primary tumor tissues in patients with colorectal carcinomas displaying microsatellite instability. II. To test the hypothesis that changes in the electrophoretic mobility profile of microsatellite biomarkers in liquid biopsies from patients with colorectal carcinoma correlate with therapeutic responsiveness measured based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria. III. To determine whether microsatellite alleles generated as a result of microsatellite instability detectable in liquid biopsy specimens from patients with colorectal carcinoma represent the entire cancer cell population or only a subset of cancer cells differentially affected by genomic instability. OUTLINE: Participants undergo collection of blood samples to evaluate microsatellite instability via serial liquid biopsies at baseline, then every 6 weeks and at progression or 9 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03594448
Study type	Observational
Source	University of Southern California
Contact	Rabia Rehman
Phone	323-865-0460
Email	Rabia.Rehman@med.usc.edu
Status	Recruiting
Phase
Start date	September 5, 2018
Completion date	September 5, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03986541` - AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer
Completed	`NCT01570452` - Matrilysin Expression in Different Stages of Colorectal Tumors	N/A
Recruiting	`NCT05354817` - Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin	Phase 2
Recruiting	`NCT05576896` - Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory	Phase 2
Completed	`NCT04715061` - Impact of Aerobic Exercise on Immune Response and Side Effects of Cancer Treatments	N/A
Terminated	`NCT03149679` - The p53 Colorectal Cancer Trial	Phase 2
Completed	`NCT05550701` - Prognostic Impact of Increased Lymph Node Yield in Colorectal Cancer Patients With Synchronous Distant Metastasis: a Population-based Study of the US Database and a Chinese Registry
Enrolling by invitation	`NCT04149613` - Predictive and Prognostic Value of Inflammatory Markers and microRNA in Stage IV Colorectal Cancer
Completed	`NCT04425239` - Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer	Phase 2
Completed	`NCT06329700` - Parenchymal Sparing Hepatectomy in Post-chemotherapy Liver Atrophy
Recruiting	`NCT05382741` - Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial	Phase 2
Recruiting	`NCT06342440` - Early Detection of Advanced Adenomas and Colorectal Cancer
Not yet recruiting	`NCT04917276` - Treatment Response Prediction System of mCRC Patients Based on CTC
Not yet recruiting	`NCT06296056` - Phase I Study of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Failed Prior Standard of Care	Phase 1
Recruiting	`NCT04714814` - Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis
Not yet recruiting	`NCT05451719` - Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy	Phase 2
Completed	`NCT03031444` - Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis	Phase 2/Phase 3
Completed	`NCT05164419` - Impact de la Marge de résection Sur la Survie à Long Terme et le Taux de récidive Des Patients Atteints de Cancers Colorectaux opérés au CHUS Entre 2006 et 2016 Pour Des métastases hépatiques
Recruiting	`NCT05171660` - Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer	Phase 3
Recruiting	`NCT05426005` - Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer	Phase 1/Phase 2